Enzolytics Inc (ENZC)

[Molly73]

ENZC is a 49% shareholder of IMMB BG!

Current Information as of 12.20.2020

Immunotech Laboratories Inc. (IMMB) owns 49% of Immunotech Laboratories BG and I, Dimitar Savov, own the other 51%! Immunotech Laboratories BG owns the patent for the medicinal product ITV-1 - ImmunH and has successfully conducted a clinical trial on 31 patients in "Professor Ivan Kirov" Hospital, Sofia, Bulgaria, European Union.
We have tested ImmunH on patients who suffered from HIV/AIDS in a clinical trial conducted under the strict guidelines of the European Union. The results of the clinical trial have shown:
- improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8,
- decrease in the viral load,
- a good treatment effect on opportunistic infections,
- very good compatibility with all of the other modern antiretroviral drugs,
- very good tolerance in all patients and complete absence of side effects.
We are awaiting a permission for mass use.
We have begun the construction of a pharmaceutical factory on the territory of Bulgaria, for the purpose of which, Immunotech Laboratories BG has signed a contract to buy a nearly complete factory, which remains to be restructured to adhere to the guidelines for good manufacturing practice (GMP). The factory is estimated to be operational no later than 30.06.2021.
Dimitar Savov
President
Immunotech Laboratories BG